AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 100_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 31_CD Assets_NNS pledged_VBN ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS 2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Assets_NNPS pledged_VBD Mortgages_NNS and_CC other_JJ assets_NNS pledged_VBD 90_CD 118_CD Commitments_NNS Contracts_NNS placed_VBN for_IN future_JJ capital_NN expenditure_NN not_RB provided_VBN for_IN in_IN these_DT accounts_NNS 421 500 515_CD Included_VBN in_IN the_DT above_JJ total_NN are_VBP contracts_NNS related_VBN to_TO certain_JJ product_NN purchase_NN and_CC licence_NN agreements_NNS with_IN deferred_JJ consideration_NN obligations_NNS ,_, the_DT amounts_NNS of_IN which_WDT are_VBP variable_JJ depending_VBG upon_IN particular_JJ milestone_NN achievements_NNS ._.
Sales_NNS of_IN the_DT products_NNS to_TO which_WDT these_DT milestones_NNS relate_VBP could_MD give_VB rise_VB to_TO additional_JJ payments_NNS ,_, contingent_NN upon_IN the_DT sales_NNS levels_NNS achieved_VBN ._.
Guarantees_NNS and_CC contingencies_NNS arising_VBG in_IN the_DT ordinary_JJ course_NN of_IN business_NN ,_, for_IN which_WDT no_DT security_NN has_VBZ been_VBN given_VBN ,_, are_VBP not_RB expected_VBN to_TO result_VB in_IN any_DT material_NN financial_JJ loss_NN ._.
Commitments_NNS In_IN 1982_CD Astra_NNP AB_NNP set_VBD up_RP a_DT joint_JJ venture_NN with_IN Merck_NNP &_CC Co._NNP ._.
Inc._NNP for_IN the_DT purposes_NNS of_IN selling_NN ,_, marketing_NN and_CC distributing_VBG certain_JJ Astra_NNP products_NNS in_IN the_DT US_NNP ._.
In_IN 1998_CD ,_, this_DT joint_JJ venture_NN was_VBD restructured_VBN the_DT restructuring_NN ._.
Under_IN the_DT restructuring_NN ,_, a_DT US_NNP limited_JJ partnership_NN ,_, in_IN which_WDT Merck_NNP is_VBZ the_DT limited_JJ partner_NN and_CC AstraZeneca_NNP is_VBZ the_DT general_JJ partner_NN ,_, was_VBD set_VBN up_RP and_CC AstraZeneca_NNP obtained_VBD control_NN of_IN the_DT joint_JJ ventures_NNS business_NN subject_NN to_TO certain_JJ limited_JJ partner_NN and_CC other_JJ rights_NNS held_VBN by_IN Merck_NNP and_CC its_PRP$ affiliates_NNS ._.
The_DT restructuring_NN agreements_NNS provide_VBP for_IN the_DT following_VBG ongoing_JJ payment_NN and_CC termination_NN arrangements_NNS :_: Annual_JJ contingent_JJ payments_NNS Partial_NNP Redemption_NNP First_NNP Option_NN Second_JJ Option_NN In_IN addition_NN ,_, included_VBD in_IN the_DT assets_NNS and_CC liabilities_NNS covered_VBN by_IN the_DT restructuring_NN is_VBZ a_DT loan_NN note_NN receivable_NN by_IN AstraZeneca_NNP from_IN Merck_NNP with_IN a_DT face_NN value_NN of_IN $_$ 1.4_CD bn_NN ._.
Each_DT of_IN these_DT elements_NNS is_VBZ discussed_VBN in_IN further_JJ detail_NN below_IN ._.
Under_IN the_DT terms_NNS of_IN the_DT 1998_CD restructuring_NN ,_, the_DT merger_NN in_IN 1999_CD between_IN Astra_NNP and_CC Zeneca_NNP triggered_VBD two_CD one-time_JJ payments_NNS from_IN AstraZeneca_NNP to_TO Merck_NNP :_: a_DT Lump_NNP Sum_NNP Payment_NN of_IN $_$ 809m_CD ,_, which_WDT was_VBD charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ,_, as_IN a_DT result_NN of_IN which_WDT Merck_NNP relinquished_VBD any_DT rights_NNS to_TO Zeneca_NNP products_NNS :_: and_CC an_DT Advance_NNP Payment_NN of_IN $_$ 967m_CD ._.
This_DT Advance_NNP Payment_NN was_VBD calculated_VBN as_IN the_DT then_RB net_JJ present_JJ value_NN of_IN $_$ 2.8_CD bn_NN discounted_VBN from_IN 2008_CD to_TO the_DT date_NN of_IN payment_NN at_IN a_DT rate_NN of_IN 13_CD %_NN per_IN annum_NN and_CC causes_VBZ Merck_NNP to_TO relinquish_VB any_DT rights_NNS ,_, including_VBG contingent_JJ payments_NNS on_IN future_JJ sales_NNS ,_, to_TO Astra_NNP products_NNS with_IN no_DT existing_VBG or_CC pending_VBG US_NNP patents_NNS at_IN the_DT time_NN of_IN the_DT merger_NN ._.
As_IN the_DT Advance_NNP Payment_NN provides_VBZ AstraZeneca_NNP with_IN relief_NN from_IN future_JJ payments_NNS ,_, this_DT amount_NN has_VBZ been_VBN capitalized_VBN as_IN an_DT intangible_JJ asset_NN and_CC is_VBZ being_VBG amortised_VBN over_IN 20_CD years_NNS ._.
The_DT Advance_NNP Payment_NN is_VBZ subject_JJ to_TO a_DT true-up_NN in_IN 2008_CD ,_, as_IN discussed_VBN under_IN First_NNP Option_NN below_IN ._.
Annual_JJ contingent_JJ payments_NNS AstraZeneca_NNP makes_VBZ ongoing_JJ payments_NNS to_TO Merck_NNP based_VBN on_IN sales_NNS of_IN certain_JJ of_IN its_PRP$ products_NNS in_IN the_DT US_NNP the_DT contingent_JJ payments_NNS on_IN the_DT agreement_NN products_NNS ._.
As_IN a_DT result_NN of_IN the_DT 1999_CD merger_NN ,_, these_DT contingent_JJ payments_NNS excluding_VBG those_DT in_IN respect_NN of_IN Prilosec_NNP and_CC Nexium_NNP can_MD not_RB be_VB less_JJR than_IN annual_JJ minimum_NN sums_NNS between_IN 2002_CD and_CC 2007_CD ranging_VBG from_IN $_$ 125m_CD to_TO $_$ 225m_CD ._.
The_DT payments_NNS have_VBP exceeded_VBN the_DT minimum_JJ level_NN in_IN 2003_CD and_CC 2002_CD and_CC AstraZeneca_NNP has_VBZ no_DT reason_NN to_TO believe_VB that_IN the_DT annual_JJ payments_NNS in_IN the_DT future_NN will_MD fall_VB below_IN the_DT minimum_NN obligations_NNS ._.
Partial_JJ Redemption_NN In_IN 2008_CD ,_, there_EX will_MD be_VB a_DT partial_JJ redemption_NN of_IN Mercks_NNP limited_JJ partnership_NN interest_NN which_WDT will_MD end_VB Mercks_NNP rights_NNS to_TO contingent_JJ payments_NNS in_IN respect_NN of_IN certain_JJ of_IN the_DT agreement_NN products_NNS by_IN distribution_NN to_TO Merck_NNP of_IN an_DT amount_NN calculated_VBN as_IN a_DT multiple_NN of_IN the_DT average_JJ annual_JJ contingent_JJ payments_NNS from_IN 2005_CD to_TO 2007_CD on_IN the_DT relevant_JJ products_NNS ,_, plus_CC $_$ 750m_CD ._.
First_NNP Option_NN In_IN 2008_CD ,_, a_DT calculation_NN will_MD be_VB made_VBN of_IN the_DT Appraised_NNP Value_NNP ,_, being_VBG the_DT net_JJ present_JJ value_NN of_IN the_DT future_JJ contingent_JJ payments_NNS in_IN respect_NN of_IN all_DT agreement_NN products_NNS not_RB covered_VBN by_IN the_DT Partial_NNP Redemption_NNP ,_, other_JJ than_IN Prilosec_NNP and_CC Nexium_NNP ._.
Payment_NN of_IN this_DT amount_NN to_TO Merck_NNP in_IN 2008_CD is_VBZ ,_, however_RB ,_, contingent_NN on_IN Mercks_NNP exercise_NN of_IN the_DT First_NNP Option_NN ._.
Exercise_NN of_IN the_DT First_NNP Option_NN will_MD require_VB AstraZeneca_NNP to_TO re-purchase_VB Mercks_NNPS interest_NN in_IN these_DT products_NNS ._.
Should_MD Merck_NNP not_RB exercise_VB this_DT option_NN in_IN 2008_CD ,_, AstraZeneca_NNP may_MD exercise_VB it_PRP in_IN 2010_CD for_IN a_DT sum_NN equal_JJ to_TO the_DT 2008_CD Appraised_NNP Value_NNP ._.
If_IN neither_DT Merck_NNP nor_CC AstraZeneca_NNP exercise_VBP the_DT option_NN ,_, the_DT contingent_JJ payment_NN arrangements_NNS in_IN respect_NN of_IN these_DT agreement_NN products_NNS will_MD continue_VB and_CC the_DT Appraised_NNP Value_NNP will_MD not_RB be_VB paid_VBN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2003_CD 101_CD 31_CD Assets_NNS pledged_VBN ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD In_IN addition_NN ,_, in_IN 2008_CD there_EX will_MD be_VB a_DT true-up_NN of_IN the_DT Advance_NNP Payment_NN ._.
The_DT calculation_NN of_IN this_DT will_MD be_VB based_VBN on_IN a_DT multiple_NN of_IN the_DT average_JJ annual_JJ contingent_JJ payments_NNS from_IN 2005_CD to_TO 2007_CD in_IN respect_NN of_IN all_PDT the_DT agreement_NN products_NNS with_IN the_DT exception_NN of_IN Prilosec_NNP and_CC Nexium_NNP subject_JJ to_TO a_DT minimum_NN of_IN $_$ 6.6_CD bn_NN ,_, plus_CC other_JJ defined_VBN amounts_NNS totalling_VBG $_$ 912m_CD ._.
It_PRP is_VBZ then_RB reduced_VBN by_IN the_DT Appraised_NNP Value_NNP whether_IN paid_VBN or_CC not_RB ,_, the_DT Partial_NNP Redemption_NNP and_CC the_DT Advance_NNP Payment_NN at_IN its_PRP$ undiscounted_JJ amount_NN of_IN $_$ 2.8_CD bn_NN to_TO determine_VB the_DT true-up_JJ amount_NN ._.
The_DT true-up_NN will_MD be_VB settled_VBN in_IN 2008_CD irrespective_RB of_IN whether_IN the_DT First_NNP Option_NN is_VBZ exercised_VBN and_CC this_DT could_MD result_VB in_IN a_DT further_JJ payment_NN by_IN AstraZeneca_NNP to_TO Merck_NNP or_CC a_DT payment_NN by_IN Merck_NNP to_TO AstraZeneca_NNP ._.
Should_MD Merck_NNP exercise_NN the_DT First_NNP Option_NN in_IN 2008_CD ,_, AstraZeneca_NNP will_MD make_VB payments_NNS in_IN respect_NN of_IN the_DT Partial_NNP Redemption_NNP ,_, the_DT First_NNP Option_NN and_CC the_DT true-up_JJ totalling_VBG a_DT minimum_NN of_IN $_$ 4.7_CD bn_NN ._.
If_IN AstraZeneca_NNP exercises_VBZ the_DT First_NNP Option_NN in_IN 2010_CD ,_, the_DT combined_VBN effect_NN will_MD involve_VB a_DT minimum_JJ aggregate_JJ amount_NN payable_JJ to_TO Merck_NNP in_IN 2008_CD and_CC 2010_CD of_IN the_DT same_JJ amount_NN ._.
Loan_NN Note_NN Receivable_NNP In_IN 2008_CD ,_, at_IN the_DT same_JJ time_NN as_IN the_DT settlement_NN of_IN the_DT Partial_NNP Redemption_NNP and_CC the_DT true-up_NN ,_, Merck_NNP will_MD settle_VB the_DT loan_NN note_NN receivable_NN by_IN paying_VBG AstraZeneca_NNP $_$ 1.4_CD bn_NN ._.
Second_JJ Option_NN A_DT Second_JJ Option_NN exists_VBZ whereby_WRB AstraZeneca_NNP has_VBZ the_DT option_NN to_TO re-purchase_VB Mercks_NNP interests_NNS in_IN Prilosec_NNP and_CC Nexium_NNP in_IN the_DT US_NNP ._.
This_DT option_NN is_VBZ exercisable_JJ by_IN AstraZeneca_NNP two_CD years_NNS after_IN the_DT exercise_NN of_IN the_DT First_NNP Option_NN ,_, whether_IN the_DT First_NNP Option_NN is_VBZ exercised_VBN in_IN either_DT 2008_CD or_CC 2010_CD ._.
Exercise_NN of_IN the_DT Second_JJ Option_NN by_IN AstraZeneca_NNP at_IN a_DT later_JJ date_NN is_VBZ also_RB provided_VBN for_IN in_IN 2017_CD or_CC if_IN combined_VBN annual_JJ sales_NNS of_IN the_DT two_CD products_NNS fall_VBP below_IN a_DT minimum_JJ amount_NN provided_VBN ,_, in_IN each_DT case_NN ,_, that_IN the_DT First_NNP Option_NN has_VBZ been_VBN exercised_VBN ._.
The_DT exercise_NN price_NN for_IN the_DT Second_JJ Option_NN is_VBZ the_DT fair_JJ value_NN of_IN these_DT product_NN rights_NNS as_IN determined_VBN at_IN the_DT time_NN of_IN exercise_NN ._.
If_IN the_DT Second_JJ Option_NN is_VBZ exercised_VBN ,_, Merck_NNP will_MD have_VB no_DT further_JJ rights_NNS to_TO contingent_JJ payments_NNS from_IN AstraZeneca_NNP ._.
Environmental_JJ costs_NNS and_CC liabilities_NNS The_DT Groups_NNS expenditure_NN on_IN environmental_JJ protection_NN ,_, including_VBG both_DT capital_NN and_CC revenue_NN items_NNS ,_, relates_VBZ to_TO costs_NNS which_WDT are_VBP necessary_JJ for_IN meeting_VBG current_JJ good_JJ practice_NN standards_NNS and_CC legal_JJ and_CC regulatory_JJ requirements_NNS for_IN processes_NNS and_CC products_NNS ._.
They_PRP are_VBP an_DT integral_JJ part_NN of_IN normal_JJ ongoing_JJ expenditure_NN for_IN maintaining_VBG the_DT Groups_NNS R&D_NNP and_CC manufacturing_VBG capacity_NN and_CC product_NN ranges_NNS and_CC are_VBP not_RB separated_VBN from_IN overall_JJ operating_NN and_CC development_NN costs_NNS ._.
There_EX are_VBP no_DT known_VBN changes_NNS in_IN legal_JJ ,_, regulatory_JJ or_CC other_JJ requirements_NNS resulting_VBG in_IN material_NN changes_NNS to_TO the_DT levels_NNS of_IN expenditure_NN for_IN 2001_CD ,_, 2002_CD or_CC 2003_CD ._.
In_IN addition_NN to_TO expenditure_NN for_IN meeting_NN current_JJ and_CC foreseen_VBN environmental_JJ protection_NN requirements_NNS ,_, the_DT Group_NNP incurs_VBZ substantial_JJ costs_NNS in_IN investigating_VBG and_CC cleaning_VBG up_RP land_NN and_CC groundwater_NN contamination_NN ._.
In_IN particular_JJ ,_, AstraZeneca_NNP and_CC or_CC its_PRP$ affiliates_NNS have_VBP environmental_JJ liabilities_NNS at_IN some_DT currently_RB or_CC formerly_RB owned_VBN ,_, leased_VBN and_CC third_JJ party_NN sites_NNS in_IN the_DT US_NNP and_CC Europe_NNP ._.
In_IN the_DT US_NNP ,_, the_DT AstraZeneca_NNP affiliate_NN ,_, Zeneca_NNP Inc._NNP and_CC or_CC its_PRP$ indemnitees_NNS ,_, have_VBP been_VBN named_VBN as_IN potentially_RB responsible_JJ parties_NNS PRPs_NNS or_CC defendants_NNS at_IN approximately_RB 13_CD sites_NNS where_WRB Zeneca_NNP Inc._NNP is_VBZ likely_JJ to_TO incur_VB future_JJ investigation_NN ,_, remediation_NN or_CC operation_NN and_CC maintenance_NN costs_NNS under_IN federal_JJ or_CC state_NN ,_, statutory_JJ or_CC common_JJ law_NN environmental_JJ liability_NN allocations_NNS schemes_NNS ._.
Similarly_RB ,_, the_DT AstraZeneca_NNP affiliate_NN ,_, Stauffer_NNP Management_NNP Company_NNP LLC_NNP SMC_NNP ,_, which_WDT was_VBD established_VBN in_IN 1987_CD to_TO own_VB and_CC manage_VB certain_JJ assets_NNS of_IN Stauffer_NNP Chemical_NNP Company_NNP acquired_VBD that_DT year_NN ,_, and_CC or_CC its_PRP$ indemnitees_NNS ,_, have_VBP been_VBN named_VBN as_IN PRPs_NNS or_CC defendants_NNS at_IN approximately_RB 29_CD sites_NNS where_WRB SMC_NNP is_VBZ likely_JJ to_TO incur_VB future_JJ investigation_NN ,_, remediation_NN or_CC operation_NN and_CC maintenance_NN costs_NNS under_IN federal_JJ or_CC state_NN ,_, statutory_JJ or_CC common_JJ law_NN environmental_JJ liability_NN allocations_NNS schemes_NNS ._.
In_IN Europe_NNP and_CC other_JJ parts_NNS of_IN the_DT world_NN outside_IN the_DT US_NNP ,_, AstraZeneca_NNP is_VBZ likely_JJ to_TO incur_VB costs_NNS at_IN three_CD currently_RB owned_VBN sites_NNS and_CC has_VBZ given_VBN indemnities_NNS to_TO third_JJ parties_NNS in_IN respect_NN of_IN approximately_RB 45_CD other_JJ sites_NNS ._.
These_DT environmental_JJ liabilities_NNS arise_VBP almost_RB entirely_RB from_IN legacy_NN operations_NNS that_WDT are_VBP not_RB part_NN of_IN our_PRP$ current_JJ pharmaceuticals_NNS business_NN and_CC ,_, at_IN most_JJS of_IN these_DT sites_NNS ,_, remediation_NN ,_, where_WRB required_VBN ,_, is_VBZ either_RB completed_VBN or_CC nearing_VBG completion_NN ._.
In_IN the_DT aggregate_NN ,_, however_RB ,_, significant_JJ expenditure_NN on_IN clean_JJ up_RB and_CC monitoring_NN is_VBZ likely_JJ to_TO be_VB required_VBN ._.
We_PRP have_VBP made_VBN provisions_NNS for_IN the_DT estimated_VBN costs_NNS of_IN future_JJ environmental_JJ investigation_NN ,_, remediation_NN and_CC operation_NN and_CC maintenance_NN activity_NN beyond_IN normal_JJ ongoing_JJ expenditure_NN for_IN maintaining_VBG the_DT Groups_NNS R&D_NNP and_CC manufacturing_VBG capacity_NN and_CC product_NN ranges_NNS where_WRB it_PRP is_VBZ probable_JJ that_IN we_PRP will_MD incur_VB such_JJ costs_NNS and_CC we_PRP can_MD estimate_VB such_JJ costs_NNS reliably_RB ._.
With_IN respect_NN to_TO such_JJ estimated_VBN ,_, future_JJ costs_NNS ,_, we_PRP had_VBD provisions_NNS at_IN 31_CD December_NNP 2003_CD in_IN the_DT aggregate_NN of_IN approximately_RB $_$ 145m_CD ,_, of_IN which_WDT approximately_RB $_$ 122m_CD relates_VBZ to_TO the_DT US_NNP ._.
These_DT provisions_NNS do_VBP not_RB include_VB possible_JJ ,_, additional_JJ costs_NNS that_WDT are_VBP not_RB currently_RB probable_JJ ,_, nor_CC do_VB these_DT provisions_NNS include_VBP costs_NNS that_IN ,_, by_IN agreement_NN ,_, will_MD be_VB borne_VBN by_IN viable_JJ third_JJ party_NN indemnitors_NNS ._.
In_IN addition_NN ,_, these_DT provisions_NNS :_: 1_CD include_VBP ,_, where_WRB appropriate_JJ ,_, unasserted_JJ claims_NNS where_WRB future_JJ costs_NNS are_VBP nonetheless_RB probable_JJ at_IN owned_VBN sites_NNS ,_, for_IN example_NN :_: 2_CD are_VBP based_VBN ,_, where_WRB applicable_JJ ,_, on_IN liability_NN allocation_NN or_CC cost_NN sharing_NN agreements_NNS that_IN we_PRP believe_VBP are_VBP enforceable_JJ against_IN viable_JJ third_JJ parties_NNS :_: 3_CD reflect_VBP expected_VBN insurance_NN recoveries_NNS where_WRB an_DT insurer_NN has_VBZ agreed_VBN to_TO provide_VB an_DT indemnity_NN :_: and_CC 4_CD typically_RB cover_VBP a_DT time_NN period_NN of_IN five_CD years_NNS with_IN the_DT exception_NN of_IN operation_NN and_CC maintenance_NN activity_NN ,_, which_WDT can_MD last_VB for_IN decades_NNS ._.
We_PRP are_VBP not_RB presently_RB aware_JJ of_IN any_DT circumstances_NNS or_CC uncertainties_NNS regarding_VBG the_DT viability_NN of_IN liable_JJ third_JJ parties_NNS ,_, indemnitors_NNS or_CC insurers_NNS that_WDT would_MD cause_VB us_PRP to_TO alter_VB these_DT provisions_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 102_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 31_CD Assets_NNS pledged_VBN ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD It_PRP is_VBZ possible_JJ that_IN the_DT Company_NN ,_, or_CC its_PRP$ affiliates_NNS ,_, could_MD incur_VB future_JJ environmental_JJ costs_NNS beyond_IN the_DT extent_NN of_IN our_PRP$ current_JJ provisions_NNS ._.
The_DT extent_NN of_IN such_JJ possible_JJ ,_, additional_JJ costs_NNS is_VBZ inherently_RB difficult_JJ to_TO estimate_VB due_JJ to_TO a_DT number_NN of_IN factors_NNS ,_, including_VBG ,_, but_CC not_RB limited_VBN to_TO :_: 1_CD the_DT nature_NN and_CC extent_NN of_IN claims_NNS that_WDT may_MD be_VB asserted_VBN in_IN the_DT future_NN :_: 2_CD whether_IN the_DT Company_NN or_CC any_DT of_IN its_PRP$ affiliates_NNS has_VBZ or_CC will_MD have_VB any_DT legal_JJ obligation_NN with_IN respect_NN to_TO asserted_VBD or_CC unasserted_JJ claims_NNS :_: 3_CD the_DT type_NN of_IN remedial_JJ action_NN ,_, if_IN any_DT ,_, that_WDT may_MD be_VB selected_VBN at_IN sites_NNS where_WRB the_DT remedy_NN is_VBZ presently_RB not_RB known_VBN :_: 4_LS the_DT potential_NN for_IN recoveries_NNS from_IN or_CC allocation_NN of_IN liability_NN to_TO third_JJ parties_NNS :_: 5_CD the_DT length_NN of_IN time_NN that_IN the_DT environmental_JJ investigation_NN ,_, remediation_NN and_CC liability_NN allocation_NN process_NN can_MD take_VB :_: and_CC 6_CD the_DT nature_NN of_IN any_DT future_JJ environmental_JJ legal_JJ or_CC regulatory_JJ changes_NNS that_WDT affect_VBP the_DT operation_NN of_IN our_PRP$ pharmaceuticals_NNS business_NN ._.
Notwithstanding_IN and_CC subject_JJ to_TO the_DT foregoing_NN ,_, we_PRP estimate_VBP that_IN potential_JJ additional_JJ loss_NN ,_, for_IN future_JJ environmental_JJ investigation_NN ,_, remediation_NN and_CC operation_NN and_CC maintenance_NN activity_NN above_IN and_CC beyond_IN our_PRP$ provisions_NNS ,_, could_MD be_VB ,_, in_IN the_DT aggregate_NN ,_, in_IN the_DT order_NN of_IN $_$ 30m_CD to_TO $_$ 50m_CD ._.
Legal_JJ proceedings_NNS AstraZeneca_NNP is_VBZ involved_VBN in_IN various_JJ legal_JJ proceedings_NNS considered_VBN typical_JJ to_TO its_PRP$ businesses_NNS ,_, including_VBG litigation_NN relating_VBG to_TO employment_NN ,_, product_NN liability_NN ,_, commercial_JJ disputes_NNS ,_, infringement_NN of_IN intellectual_JJ property_NN rights_NNS and_CC the_DT validity_NN of_IN certain_JJ patents_NNS ._.
The_DT more_JJR significant_JJ matters_NNS are_VBP discussed_VBN below_IN ._.
Diprivan_NNP propofol_NN In_IN August_NNP 2002_CD ,_, AstraZeneca_NNP LP_NNP received_VBD a_DT letter_NN from_IN ESI_NNP Lederle_NNP ,_, a_DT division_NN of_IN Wyeth_NNP ,_, informing_VBG AstraZeneca_NNP of_IN Wyeths_NNP intention_NN to_TO market_VB a_DT generic_JJ version_NN of_IN Diprivan_NNP prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patents_NNS covering_VBG the_DT current_JJ formulation_NN ._.
AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN Wyeth_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ._.
Through_IN a_DT series_NN of_IN transactions_NNS ,_, the_DT holder_NN of_IN the_DT relevant_JJ abbreviated_JJ new_JJ drug_NN application_NN and_CC now_RB defendant_NN in_IN AstraZenecas_NNP suit_NN is_VBZ Mayne_NNP Pharma_NNP USA_NNP Inc._NNP formerly_RB called_VBD Faulding_NNP Pharmaceutical_NNP Co._NNP ._.
Faulding_NNP Mayne_NNP responded_VBD to_TO AstraZenecas_NNP complaint_NN and_CC filed_VBD counterclaims_NNS alleging_VBG non-infringement_JJ and_CC invalidity_NN ._.
Discovery_NNP is_VBZ scheduled_VBN to_TO close_VB in_IN June_NNP 2004_CD ._.
The_DT trial_NN is_VBZ expected_VBN to_TO be_VB held_VBN no_DT earlier_JJR than_IN the_DT fourth_JJ quarter_NN of_IN 2004_CD ._.
Losec_NNP Prilosec_NNP omeprazole_NN In_IN June_NNP 1997_CD ,_, the_DT German_NNP Federal_NNP Patent_NNP Court_NNP declared_VBD invalid_JJ a_DT previously_RB granted_VBN supplementary_JJ protection_NN certificate_NN which_WDT extended_VBD protection_NN for_IN omeprazole_NN ,_, the_DT active_JJ ingredient_NN contained_VBN in_IN Losec_NNP ,_, from_IN 1999_CD to_TO 2003_CD ._.
The_DT decision_NN was_VBD appealed_VBN and_CC in_IN February_NNP 2000_CD ,_, at_IN AstraZenecas_NNP request_NN ,_, the_DT German_NNP Supreme_NNP Court_NNP decided_VBD to_TO refer_VB the_DT case_NN to_TO the_DT European_NNP Court_NNP of_IN Justice_NNP ECJ_NNP for_IN a_DT preliminary_JJ ruling_NN ._.
In_IN December_NNP 2003_CD ,_, the_DT ECJ_NNP ruled_VBD against_IN AstraZeneca_NNP on_IN all_DT questions_NNS ._.
Consequently_RB ,_, the_DT German_JJ omeprazole_NN supplementary_JJ protection_NN certificate_NN is_VBZ confirmed_VBN invalid_JJ ._.
The_DT case_NN did_VBD not_RB involve_VB any_DT financial_JJ claims_NNS ._.
In_IN March_NNP 2000_CD ,_, the_DT German_NNP Federal_NNP Patent_NNP Court_NNP declared_VBD that_IN AstraZenecas_NNP formulation_NN patent_NN for_IN omeprazole_NN was_VBD invalid_JJ ._.
The_DT decision_NN has_VBZ been_VBN appealed_VBN to_TO the_DT German_JJ Supreme_NNP Court_NNP ,_, which_WDT will_MD hear_VB the_DT case_NN in_IN March_NNP 2004_CD ._.
As_IN a_DT consequence_NN ,_, all_DT pending_VBG infringement_NN actions_NNS in_IN Germany_NNP have_VBP been_VBN stayed_VBN awaiting_VBG the_DT outcome_NN of_IN the_DT appeal_NN ._.
There_EX is_VBZ one_CD interlocutory_NN injunction_NN in_IN force_NN against_IN ratiopharm_JJ GmbH_NNP based_VBN on_IN the_DT formulation_NN patent_NN ._.
If_IN the_DT final_JJ decision_NN on_IN the_DT validity_NN of_IN the_DT formulation_NN patent_NN goes_VBZ against_IN AstraZeneca_NNP ,_, ratiopharm_NN may_MD claim_VB damages_NNS for_IN lost_VBN sales_NNS due_JJ to_TO the_DT interlocutory_JJ injunction_NN ._.
In_IN 1998_CD ,_, Astra_NNP filed_VBD suits_NNS in_IN the_DT US_NNP against_IN Andrx_NNP Pharmaceuticals_NNP ,_, Inc._NNP and_CC Genpharm_NNP ,_, Inc._NNP ._.
This_DT followed_VBD the_DT filing_NN of_IN abbreviated_JJ new_JJ drug_NN applications_NNS by_IN Andrx_NNP and_CC Genpharm_NNP with_IN the_DT US_NNP Food_NNP and_CC Drug_NNP Administration_NNP FDA_NNP concerning_VBG the_DT two_CD companies_NNS intention_NN to_TO market_NN generic_JJ omeprazole_NN products_NNS in_IN the_DT US_NNP ._.
During_IN 1999_CD ,_, Astra_NNP also_RB filed_VBD suits_NNS against_IN Kremers_NNP Urban_NNP Development_NNP Company_NNP and_CC Schwarz_NNP Pharma_NNP ,_, Inc._NNP and_CC against_IN Cheminor_NNP Drugs_NNPS Ltd._NNP ._.
Reddy-Cheminor_NNP Inc._NNP and_CC Schein_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
During_IN 2000_CD ,_, AstraZeneca_NNP filed_VBD further_JJ suits_NNS against_IN Lek_NNP Pharmaceutical_NNP and_CC Chemical_NNP Company_NNP d._FW d._FW Impax_NNP Laboratories_NNPS Inc._NNP ._.
Eon_NNP Labs_NNPS Manufacturing_NNP Inc._NNP and_CC Mylan_NNP Pharmaceuticals_NNP Inc._NNP ._.
During_IN 2001_CD ,_, AstraZeneca_NNP filed_VBD further_JJ suits_NNS against_IN Torpharm_NNP ,_, Inc._NNP and_CC Zenith_NNP Goldline_NNP Pharmaceuticals_NNP ,_, Inc._NNP now_RB known_VBN as_IN Ivax_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
The_DT basis_NN for_IN the_DT proceedings_NNS is_VBZ that_IN the_DT actions_NNS of_IN all_PDT the_DT companies_NNS infringe_VBP several_JJ patents_NNS relating_VBG to_TO omeprazole_VB Prilosec_NNP in_IN the_DT US_NNP ._.
The_DT cases_NNS are_VBP proceeding_VBG under_IN the_DT US_NNP Hatch-Waxman_NNP legislation_NN ._.
Anti-trust_JJ counterclaims_NNS have_VBP been_VBN filed_VBN by_IN Andrx_NNP ,_, Torpharm_NNP ,_, Impax_NNP ,_, Eon_NNP and_CC Lek_NNP ._.
The_DT trial_NN against_IN Andrx_NNP ,_, Genpharm_NNP ,_, Kremers_NNP Urban_NNP Development_NNP Company_NNP and_CC Cheminor_NNP started_VBD in_IN December_NNP 2001_CD and_CC ended_VBN in_IN July_NNP 2002_CD ._.
In_IN October_NNP 2002_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ruled_VBD that_IN two_CD AstraZeneca_NNP patents_NNS 230_CD and_CC 505_CD relating_VBG to_TO the_DT formulation_NN of_IN omeprazole_NN are_VBP valid_JJ until_IN 2007_CD ,_, that_IN Andrx_NNP ,_, Genpharm_NNP and_CC Cheminor_NNP all_DT infringed_VBN both_DT patents_NNS but_CC that_IN Kremers_NNP Urban_NNP Development_NNP Company_NNP did_VBD not_RB infringe_VB either_DT patent_NN ._.
The_DT court_NN did_VBD not_RB rule_NN on_IN the_DT 281_CD patent_NN relating_VBG to_TO a_DT manufacturing_NN process_NN for_IN omeprazole_JJ formulations_NNS in_IN respect_NN of_IN which_WDT AstraZeneca_NNP has_VBZ sued_VBN Andrx_NNP only_RB ._.
AstraZeneca_NNP appealed_VBD the_DT judgement_NN with_IN regard_NN to_TO noninfringement_NN and_CC Kremers_NNP Urban_NNP Development_NNP Company_NNP ,_, Andrx_NNP ,_, Genpharm_NNP and_CC Cheminor_NNP appealed_VBD the_DT decision_NN with_IN regard_NN to_TO infringement_NN and_CC validity_NN of_IN the_DT patents_NNS ._.
The_DT appeal_NN hearings_NNS took_VBD place_NN in_IN December_NNP 2003_CD and_CC the_DT original_JJ decision_NN of_IN the_DT lower_JJR court_NN was_VBD affirmed_VBN by_IN the_DT appeal_NN court_NN in_IN all_DT respects_NNS ._.
In_IN April_NNP 2001_CD ,_, Andrx_NNP filed_VBD a_DT case_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP against_IN AstraZeneca_NNP ,_, Merck_NNP &_CC Co._NNP ._.
Inc._NNP and_CC the_DT FDA_NNP alleging_VBG that_IN the_DT listing_NN of_IN certain_JJ patents_NNS in_IN the_DT FDAs_NNP Orange_NNP Book_NNP was_VBD improper_JJ and_CC constituted_VBD violations_NNS of_IN certain_JJ provisions_NNS of_IN the_DT Sherman_NNP Act_NNP ,_, the_DT US_NNP federal_JJ anti-trust_JJ legislation_NN ,_, and_CC a_DT state_NN statute_NN analogous_JJ to_TO the_DT federal_JJ anti-trust_JJ laws_NNS ._.
Andrx_NNP seeks_VBZ injunctive_JJ relief_NN compelling_JJ the_DT parties_NNS to_TO delist_VB omeprazole-related_JJ patents_NNS it_PRP claims_VBZ were_VBN improperly_RB listed_VBN in_IN the_DT Orange_NNP Book_NNP and_CC prohibiting_VBG the_DT defendants_NNS from_IN using_VBG patents_NNS to_TO delay_VB the_DT effective_JJ date_NN of_IN the_DT FDAs_NNS approval_NN of_IN Andrxs_NNP ANDA_NNP for_IN omeprazole_NN ._.
AstraZeneca_NNP and_CC Merck_NNP have_VBP filed_VBN motions_NNS to_TO dismiss_VB the_DT case_NN ,_, which_WDT are_VBP pending_VBG ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2003_CD 103_CD 31_CD Assets_NNS pledged_VBN ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD In_IN October_NNP 2000_CD ,_, the_DT Federal_NNP Court_NNP of_IN Australia_NNP Full_NNP Court_NNP handed_VBD down_RP a_DT patent_NN ruling_NN pertaining_VBG to_TO omeprazole_VB in_IN connection_NN with_IN a_DT dispute_NN between_IN AstraZeneca_NNP and_CC the_DT generic_JJ company_NN ,_, Alphapharm_NNP Pty_NNP Ltd._NNP ._.
The_DT court_NN declared_VBD that_IN AstraZenecas_NNP formulation_NN patent_NN was_VBD invalid_JJ ._.
In_IN November_NNP 2001_CD ,_, AstraZeneca_NNP applied_VBD for_IN special_JJ leave_NN to_TO appeal_VB the_DT decision_NN to_TO the_DT High_NNP Court_NNP of_IN Australia_NNP and_CC this_DT application_NN was_VBD granted_VBN in_IN December_NNP 2001_CD ._.
The_DT appeal_NN was_VBD heard_VBN by_IN the_DT High_NNP Court_NNP in_IN May_NNP 2002_CD and_CC in_IN December_NNP 2002_CD the_DT High_NNP Court_NNP reversed_VBD the_DT judgement_NN of_IN the_DT lower_JJR court_NN ._.
The_DT High_NNP Court_NNP ruled_VBD that_IN AstraZenecas_NNP formulation_NN patent_NN is_VBZ valid_JJ and_CC that_IN the_DT case_NN should_MD be_VB returned_VBN to_TO the_DT lower_JJR court_NN for_IN determination_NN of_IN the_DT remaining_VBG issues_NNS ._.
In_IN July_NNP 2003_CD ,_, the_DT case_NN was_VBD settled_VBN ._.
During_IN 2000_CD ,_, AstraZeneca_NNP was_VBD granted_VBN interlocutory_JJ injunctions_NNS based_VBN on_IN certain_JJ of_IN AstraZenecas_NNP omeprazole_NN patents_NNS and_CC supplementary_JJ protection_NN certificates_NNS against_IN the_DT generic_JJ company_NN ,_, Scandinavian_NNP AB_NNP Scand_NNP Pharm_NNP ,_, in_IN Denmark_NNP and_CC Norway_NNP ._.
In_IN October_NNP 2001_CD ,_, Oslo_NNP City_NNP Court_NNP in_IN Norway_NNP found_VBD that_IN Scand_NNP Pharm_NNP had_VBD infringed_VBN AstraZenecas_NNP formulation_NN patent_NN for_IN omeprazole_NN ._.
At_IN the_DT same_JJ time_NN ,_, the_DT court_NN declared_VBD AstraZenecas_NNP formulation_NN patent_NN valid_JJ ._.
As_IN a_DT result_NN of_IN the_DT Norwegian_JJ case_NN ,_, Scand_NNP Pharm_NNP can_MD not_RB sell_VB its_PRP$ omeprazole_JJ product_NN in_IN Norway_NNP ._.
Furthermore_RB ,_, it_PRP is_VBZ also_RB prevented_VBN from_IN selling_VBG its_PRP$ omeprazole_JJ product_NN in_IN Denmark_NNP pending_VBG the_DT outcome_NN of_IN the_DT main_JJ action_NN in_IN the_DT Danish_JJ case_NN ._.
If_IN the_DT final_JJ decisions_NNS in_IN these_DT cases_NNS are_VBP against_IN AstraZeneca_NNP ,_, Scand_NNP Pharm_NNP may_MD claim_VB damages_NNS for_IN lost_VBN sales_NNS due_JJ to_TO the_DT interlocutory_JJ injunctions_NNS ._.
In_IN the_DT Netherlands_NNP ,_, Pharmachemie_NNP BV_NNP filed_VBD a_DT claim_NN against_IN two_CD AstraZeneca_NNP companies_NNS in_IN 2002_CD alleging_VBG that_IN AstraZeneca_NNP had_VBD misused_VBN its_PRP$ exclusive_JJ rights_NNS in_IN the_DT Netherlands_NNP in_IN relation_NN to_TO the_DT expiration_NN date_NN for_IN AstraZenecas_NNP supplementary_JJ protection_NN certificate_NN for_IN omeprazole_NN ._.
In_IN February_NNP 2003_CD ,_, the_DT case_NN was_VBD withdrawn_VBN by_IN Pharmachemie_NNP ._.
AstraZeneca_NNP has_VBZ been_VBN and_CC continues_VBZ to_TO be_VB involved_VBN in_IN numerous_JJ proceedings_NNS in_IN Canada_NNP involving_VBG Genpharm_NNP ,_, Reddy_NNP Cheminor_NNP ,_, Rhoxalpharma_NNP and_CC Apotex_NNP ._.
These_DT cases_NNS relate_VBP to_TO omeprazole_VB capsules_NNS or_CC omeprazole_NN magnesium_NN tablets_NNS and_CC involve_VB various_JJ patents_NNS ._.
AstraZeneca_NNP could_MD potentially_RB be_VB liable_JJ for_IN damages_NNS in_IN some_DT cases_NNS ._.
However_RB ,_, there_EX are_VBP no_DT financial_JJ claims_NNS currently_RB being_VBG made_VBN against_IN AstraZeneca_NNP in_IN Canada_NNP in_IN any_DT litigation_NN in_IN respect_NN of_IN omeprazole_NN capsules_NNS or_CC omeprazole_NN magnesium_NN tablets_NNS ._.
In_IN February_NNP 2000_CD ,_, the_DT European_JJ Commission_NNP commenced_VBD an_DT investigation_NN relating_VBG to_TO certain_JJ omeprazole_NN intellectual_JJ property_NN rights_NNS ,_, and_CC associated_VBN regulatory_JJ and_CC patent_NN infringement_NN litigation_NN ._.
The_DT investigation_NN is_VBZ pursuant_JJ to_TO Article_NNP 82_CD of_IN the_DT EC_NNP Treaty_NNP ,_, which_WDT prohibits_VBZ an_DT abuse_NN of_IN a_DT dominant_JJ position_NN ._.
The_DT investigation_NN was_VBD precipitated_VBN by_IN a_DT complaint_NN by_IN a_DT party_NN to_TO a_DT number_NN of_IN patent_NN and_CC other_JJ proceedings_NNS involving_VBG AstraZeneca_NNP ._.
AstraZeneca_NNP has_VBZ ,_, in_IN accordance_NN with_IN its_PRP$ corporate_JJ policy_NN ,_, co-operated_JJ with_IN the_DT Commission_NNP ._.
In_IN July_NNP 2003_CD ,_, the_DT Commission_NNP served_VBD a_DT Statement_NN of_IN Objections_NNS on_IN AstraZeneca_NNP ,_, referring_VBG to_TO alleged_VBN infringements_NNS regarding_VBG the_DT obtaining_VBG of_IN supplementary_JJ protection_NN certificates_NNS for_IN omeprazole_NN in_IN certain_JJ European_JJ countries_NNS :_: and_CC regarding_VBG AstraZenecas_NNP replacement_NN of_IN omeprazole_NN capsules_NNS by_IN omeprazole_NN MUPS_NNP tablets_NNS and_CC withdrawal_NN of_IN capsule_NN marketing_NN authorisations_NNS in_IN three_CD European_JJ countries_NNS ._.
AstraZeneca_NNP has_VBZ replied_VBN fully_RB to_TO the_DT Commission_NNP ,_, explaining_VBG why_WRB its_PRP$ actions_NNS were_VBD in_IN AstraZenecas_NNP view_NN lawful_JJ ._.
The_DT Commission_NNP is_VBZ considering_VBG AstraZenecas_NNP submission_NN ,_, and_CC an_DT oral_JJ hearing_NN is_VBZ scheduled_VBN to_TO take_VB place_NN ._.
If_IN ,_, ultimately_RB ,_, and_CC subject_JJ to_TO any_DT appeals_NNS to_TO the_DT Court_NNP of_IN First_NNP Instance_NNP and_CC the_DT European_NNP Court_NNP of_IN Justice_NNP it_PRP is_VBZ held_VBN that_IN Article_NNP 82_CD has_VBZ been_VBN infringed_VBN ,_, then_RB there_EX may_MD be_VB a_DT liability_NN to_TO fines_NNS and_CC or_CC other_JJ measures_NNS which_WDT can_MD be_VB imposed_VBN by_IN the_DT Commission_NNP ._.
There_EX could_MD also_RB be_VB liability_NN for_IN alleged_JJ losses_NNS incurred_VBN by_IN aggrieved_JJ third_JJ parties_NNS ._.
It_PRP is_VBZ not_RB possible_JJ ,_, at_IN the_DT present_JJ time_NN ,_, to_TO quantify_VB any_DT such_JJ liabilities_NNS as_IN no_DT fines_NNS have_VBP to_TO date_NN been_VBN imposed_VBN and_CC no_DT claims_NNS for_IN damages_NNS have_VBP been_VBN received_VBN ._.
Moreover_RB ,_, bearing_VBG in_IN mind_NN the_DT timescales_NNS of_IN proceedings_NNS ,_, including_VBG appeals_NNS ,_, there_EX may_MD well_RB be_VB a_DT considerable_JJ period_NN before_IN any_DT such_JJ liabilities_NNS are_VBP finally_RB established_VBN even_RB if_IN ,_, which_WDT is_VBZ denied_VBN ,_, any_DT such_JJ liabilities_NNS exist_VBP ._.
Nolvadex_NNP tamoxifen_NN AstraZeneca_NNP is_VBZ a_DT co-defendant_NN with_IN Barr_NNP Laboratories_NNPS ,_, Inc._NNP in_IN numerous_JJ purported_JJ class_NN actions_NNS filed_VBN in_IN federal_JJ and_CC state_NN courts_NNS throughout_IN the_DT US_NNP ._.
All_DT of_IN the_DT state_NN court_NN actions_NNS were_VBD removed_VBN to_TO federal_JJ court_NN and_CC have_VBP been_VBN consolidated_JJ ,_, along_IN with_IN all_DT of_IN the_DT cases_NNS originally_RB filed_VBN in_IN federal_JJ court_NN ,_, in_IN a_DT federal_JJ multi-district_JJ litigation_NN proceeding_VBG pending_VBG in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN New_NNP York_NNP ._.
Some_DT of_IN the_DT cases_NNS were_VBD filed_VBN by_IN plaintiffs_NNS representing_VBG a_DT putative_JJ class_NN of_IN consumers_NNS who_WP purchased_VBD tamoxifen_NN ._.
The_DT other_JJ cases_NNS were_VBD filed_VBN on_IN behalf_NN of_IN a_DT putative_JJ class_NN of_IN third_JJ party_NN payers_NNS including_VBG health_NN maintenance_NN organizations_NNS ,_, insurers_NNS and_CC other_JJ managed_VBN care_NN providers_NNS and_CC health_NN plans_NNS that_WDT have_VBP reimbursed_VBN or_CC otherwise_RB paid_VBN for_IN prescriptions_NNS of_IN tamoxifen_NN ._.
The_DT plaintiffs_NNS allege_VBP that_IN they_PRP paid_VBD supra-competitive_JJ and_CC monopolistic_JJ prices_NNS for_IN tamoxifen_NN as_IN a_DT result_NN of_IN the_DT settlement_NN of_IN patent_NN litigation_NN between_IN Zeneca_NNP and_CC Barr_NNP in_IN 1993_CD ._.
The_DT plaintiffs_NNS seek_VBP injunctive_JJ relief_NN ,_, treble_JJ damages_NNS under_IN the_DT anti-trust_JJ laws_NNS ,_, disgorgement_NN and_CC restitution_NN ._.
In_IN April_NNP 2002_CD ,_, AstraZeneca_NNP filed_VBD a_DT motion_NN to_TO dismiss_VB the_DT cases_NNS for_IN failure_NN to_TO state_VB a_DT cause_NN of_IN action_NN ._.
In_IN May_NNP 2003_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN New_NNP York_NNP granted_VBD AstraZenecas_NNP motion_NN to_TO dismiss_VB ._.
The_DT plaintiffs_NNS have_VBP appealed_VBN the_DT decision_NN ._.
In_IN August_NNP 2002_CD ,_, AstraZenecas_NNP US_NNP distribution_NN agreement_NN with_IN Barr_NNP Laboratories_NNPS ,_, Inc._NNP for_IN non-branded_JJ tamoxifen_NN expired_VBD ,_, as_IN did_VBD AstraZenecas_NNP patent_NN for_IN Nolvadex_NNP tamoxifen_NN ._.
At_IN the_DT same_JJ time_NN ,_, a_DT six_CD month_NN period_NN of_IN market_NN exclusivity_NN ,_, awarded_VBN by_IN the_DT US_NNP Food_NNP and_CC Drug_NNP Administration_NNP in_IN connection_NN with_IN the_DT successful_JJ completion_NN of_IN certain_JJ paediatric_JJ testing_NN with_IN the_DT product_NN ,_, commenced_VBN ._.
Barr_NNP thereafter_RB commenced_VBD litigation_NN against_IN the_DT FDA_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Columbia_NNP ,_, challenging_VBG the_DT FDAs_NNS refusal_NN to_TO grant_VB Barr_NNP final_JJ approval_NN for_IN its_PRP$ own_JJ generic_JJ tamoxifen_NN prior_RB to_TO expiration_NN of_IN AstraZenecas_NNP exclusivity_NN period_NN ._.
Barr_NNP also_RB declined_VBD AstraZenecas_NNP offer_NN to_TO extend_VB the_DT distribution_NN agreement_NN through_IN the_DT end_NN of_IN the_DT exclusivity_NN period_NN ._.
Therefore_RB ,_, in_IN October_NNP 2002_CD ,_, AstraZeneca_NNP began_VBD shipping_VBG its_PRP$ own_JJ nonbranded_JJ tamoxifen_NN to_TO customers_NNS to_TO ensure_VB an_DT uninterrupted_JJ supply_NN to_TO patients_NNS ._.
In_IN December_NNP 2002_CD ,_, the_DT Court_NNP held_VBD that_IN Barr_NNP could_MD not_RB obtain_VB final_JJ FDA_NNP approval_NN for_IN its_PRP$ own_JJ generic_JJ tamoxifen_NN prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP paediatric_JJ exclusivity_NN for_IN Nolvadex_NNP ._.
In_IN January_NNP 2003_CD ,_, AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 104_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 31_CD Assets_NNS pledged_VBN ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD Barr_NNP made_VBD a_DT claim_NN that_IN AstraZeneca_NNP improperly_RB thwarted_VBD Barrs_NNP entry_NN into_IN the_DT tamoxifen_JJ market_NN and_CC caused_VBD Barr_NNP monetary_JJ damages_NNS ._.
Plendil_NNP felodipine_NN In_IN August_NNP 2000_CD ,_, AstraZeneca_NNP LP_NNP received_VBD a_DT letter_NN from_IN Mutual_JJ Pharmaceutical_NNP Co._NNP ._.
Inc._NNP informing_VBG AstraZeneca_NNP of_IN Mutuals_NNP intention_NN to_TO market_VB a_DT generic_JJ version_NN of_IN AstraZenecas_NNP Plendil_NNP extended_VBD release_NN tablets_NNS felodipine_VBP prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patent_NN covering_VBG the_DT extended_JJ release_NN formulation_NN ._.
AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN Mutual_JJ in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP ._.
Mutual_JJ responded_VBD and_CC filed_VBD counterclaims_NNS alleging_VBG non-infringement_JJ and_CC invalidity_NN ._.
In_IN March_NNP 2003_CD ,_, the_DT District_NNP Court_NNP granted_VBD summary_NN judgement_NN in_IN favor_NN of_IN AstraZeneca_NNP as_IN to_TO the_DT infringement_NN claim_NN holding_VBG that_IN Mutual_JJ infringed_VBN AstraZenecas_NNP formulation_NN patent_NN ._.
In_IN August_NNP 2003_CD ,_, the_DT District_NNP Court_NNP granted_VBD summary_NN judgement_NN in_IN favor_NN of_IN AstraZeneca_NNP as_IN to_TO the_DT validity_NN claim_NN holding_VBG that_IN AstraZenecas_NNP patent_NN is_VBZ valid_JJ ._.
Mutual_NNP has_VBZ filed_VBN a_DT notice_NN of_IN appeal_NN as_IN to_TO both_DT of_IN these_DT decisions_NNS to_TO the_DT US_NNP District_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Federal_NNP Circuit_NNP ._.
Seroquel_NNP quetiapine_NN fumarate_NN AstraZeneca_NNP PLC_NNP and_CC AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP have_VBP been_VBN named_VBN as_IN defendants_NNS in_IN the_DT case_NN of_IN Susan_NNP Zehel-Miller_NNP et_FW al._FW ._.
v._CC AstraZenaca_NNP -LRB-_-LRB- sic_JJ -RRB-_-RRB- ,_, AstraZenaca_NNP Pharmaceuticals_NNP ,_, LP_NNP -LRB-_-LRB- sic_JJ -RRB-_-RRB- ,_, a_DT putative_JJ class_NN action_NN suit_NN filed_VBN in_IN August_NNP 2003_CD in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Middle_NNP District_NNP of_IN Florida_NNP ._.
The_DT named_VBN plaintiffs_NNS are_VBP seeking_VBG damages_NNS and_CC injunctive_JJ relief_NN on_IN behalf_NN of_IN a_DT purported_JJ class_NN consisting_VBG of_IN all_DT persons_NNS in_IN the_DT United_NNP States_NNPS who_WP purchased_VBD and_CC or_CC used_VBN Seroquel_NNP ._.
Although_IN the_DT scope_NN of_IN the_DT allegations_NNS in_IN the_DT complaint_NN is_VBZ very_RB broad_JJ ,_, the_DT primary_JJ focus_NN appears_VBZ to_TO be_VB the_DT contention_NN that_IN the_DT Company_NN failed_VBD to_TO provide_VB adequate_JJ warnings_NNS in_IN connection_NN with_IN an_DT alleged_JJ association_NN between_IN Seroquel_NNP and_CC the_DT onset_NN of_IN diabetes_NN ._.
AstraZeneca_NNP denies_VBZ the_DT material_NN allegations_NNS of_IN the_DT plaintiffs_NNS complaint_NN and_CC is_VBZ vigorously_RB defending_VBG the_DT litigation_NN ._.
Toprol-XL_JJ metoprolol_NN succinate_VB In_IN March_NNP 2003_CD ,_, AstraZeneca_NNP LP_NNP received_VBD a_DT letter_NN from_IN KV_NNP Pharmaceutical_NNP Company_NNP informing_VBG AstraZeneca_NNP of_IN KVs_NNP intent_NN to_TO market_VB a_DT generic_JJ version_NN of_IN Toprol-XL_JJ tablets_NNS in_IN the_DT 200mg_JJ dosage_NN prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patents_NNS covering_VBG the_DT substance_NN and_CC its_PRP$ formulation_NN ,_, the_DT latest_JJS of_IN which_WDT expires_VBZ in_IN March_NNP 2008_CD ._.
AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN KV_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Missouri_NNP ._.
KV_NNP responded_VBD and_CC filed_VBD counterclaims_NNS alleging_VBG non-infringement_JJ and_CC invalidity_NN ._.
Discovery_NNP is_VBZ scheduled_VBN to_TO close_VB in_IN August_NNP 2004_CD ._.
The_DT trial_NN is_VBZ scheduled_VBN for_IN April_NNP 2005_CD ._.
In_IN July_NNP 2003_CD ,_, AstraZeneca_NNP received_VBD a_DT similar_JJ letter_NN from_IN KV_NNP with_IN respect_NN to_TO the_DT 100mg_JJ dosage_NN of_IN Toprol-XL_JJ tablets_NNS ._.
AstraZeneca_NNP filed_VBD another_DT patent_NN infringement_NN complaint_NN against_IN KV_NNP in_IN the_DT same_JJ court_NN ._.
KV_NNP filed_VBD counterclaims_NNS alleging_VBG non-infringement_JJ and_CC invalidity_NN ._.
This_DT case_NN has_VBZ been_VBN consolidated_VBN with_IN the_DT initial_JJ case_NN ._.
In_IN December_NNP 2003_CD ,_, AstraZeneca_NNP received_VBD a_DT letter_NN from_IN Andrx_NNP Pharmaceuticals_NNP LLC_NNP with_IN notification_NN that_IN Andrx_NNP has_VBZ filed_VBN an_DT abbreviated_JJ new_JJ drug_NN application_NN to_TO market_VB a_DT generic_JJ form_NN of_IN Toprol-XL_JJ extended_JJ release_NN tablets_NNS in_IN the_DT 50mg_JJ dose_NN which_WDT it_PRP intends_VBZ to_TO sell_VB prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patents_NNS listed_VBN in_IN the_DT FDAs_NNP Orange_NNP Book_NNP ,_, the_DT latest_JJS of_IN which_WDT expires_VBZ in_IN March_NNP 2008_CD ._.
Andrx_NNP claims_VBZ that_IN each_DT of_IN the_DT listed_VBN patents_NNS are_VBP invalid_JJ and_CC or_CC not_RB infringed_VBN ._.
AstraZeneca_NNP is_VBZ considering_VBG whether_IN to_TO file_VB a_DT suit_NN for_IN patent_NN infringement_NN against_IN Andrx_NNP ._.
Zestril_NNP lisinopril_NN In_IN 1986_CD ,_, AstraZenecas_NNP predecessor_NN company_NN and_CC Merck_NNP &_CC Co._NNP ._.
Inc._NNP entered_VBD into_IN licence_NN agreements_NNS under_IN which_WDT AstraZeneca_NNP was_VBD granted_VBN the_DT right_NN to_TO make_VB ,_, use_VB and_CC sell_VB lisinopril_NN Zestril_NNP ,_, in_IN return_NN for_IN which_WDT AstraZeneca_NNP agreed_VBD to_TO pay_VB royalties_NNS to_TO Merck_NNP ._.
In_IN April_NNP 2002_CD ,_, AstraZeneca_NNP commenced_VBD arbitration_NN proceedings_NNS against_IN Merck_NNP under_IN one_CD of_IN the_DT licence_NN agreements_NNS ._.
In_IN the_DT arbitration_NN ,_, AstraZeneca_NNP sought_VBD repayment_NN of_IN approximately_RB $_$ 38m_CD of_IN prior_JJ royalty_NN amounts_NNS and_CC a_DT prospective_JJ reduction_NN in_IN the_DT royalty_NN rate_NN going_VBG forward_RB ._.
The_DT case_NN was_VBD settled_VBN in_IN May_NNP 2003_CD ._.
Under_IN the_DT settlement_NN agreement_NN ,_, Merck_NNP paid_VBD $_$ 37m_CD to_TO AstraZeneca_NNP and_CC the_DT parties_NNS agreed_VBD that_IN the_DT royalty_NN rate_NN going_VBG forward_RB would_MD not_RB be_VB reduced_VBN ._.
Zoladex_NNP goserelin_NN acetate_NN implant_VBP investigation_NN In_IN June_NNP 2003_CD ,_, AstraZeneca_NNP announced_VBD the_DT settlement_NN of_IN a_DT multi-year_JJ investigation_NN into_IN US_NNP sales_NNS and_CC marketing_NN practices_NNS for_IN Zoladex_NNP ,_, a_DT treatment_NN for_IN prostate_NN cancer_NN ._.
Under_IN the_DT terms_NNS of_IN the_DT settlement_NN ,_, AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP admitted_VBD to_TO having_VBG violated_VBN the_DT Prescription_NNP Drug_NNP Marketing_NNP Act_NNP by_IN providing_VBG free_JJ samples_NNS of_IN Zoladex_NNP to_TO physicians_NNS during_IN the_DT period_NN 1993_CD to_TO 1996_CD ,_, with_IN the_DT understanding_NN that_IN these_DT physicians_NNS would_MD bill_VB Medicare_NNP for_IN reimbursement_NN ._.
AstraZeneca_NNP also_RB settled_VBD ,_, without_IN admitting_VBG liability_NN ,_, civil_JJ claims_NNS involving_VBG allegations_NNS that_IN the_DT Company_NN provided_VBD inducements_NNS to_TO physicians_NNS to_TO purchase_VB Zoladex_NNP and_CC for_IN improperly_RB setting_VBG and_CC reporting_VBG its_PRP$ price_NN ._.
The_DT total_JJ payment_NN associated_VBN with_IN the_DT settlement_NN was_VBD $_$ 355m_CD ._.
This_DT amount_NN included_VBD funds_NNS set_VBN aside_RB to_TO cover_VB individual_JJ settlement_NN agreements_NNS with_IN the_DT states_NNS involving_VBG related_JJ claims_NNS ._.
As_IN previously_RB disclosed_VBN by_IN the_DT Company_NN ,_, in_IN 2002_CD it_PRP accrued_VBD $_$ 350m_CD to_TO cover_VB these_DT settlement_NN costs_NNS ._.
The_DT settlement_NN also_RB provides_VBZ for_IN a_DT five-year_JJ Corporate_JJ Integrity_NN Agreement_NN with_IN the_DT Office_NNP of_IN Inspector_NNP General_NNP OIG_NNP for_IN the_DT Department_NNP of_IN Health_NNP and_CC Human_NNP Services_NNPS under_IN which_WDT AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP is_VBZ required_VBN ,_, among_IN other_JJ obligations_NNS ,_, to_TO keep_VB in_IN place_NN its_PRP$ current_JJ compliance_NN program_NN and_CC provide_VB periodic_JJ reports_NNS to_TO the_DT OIG_NNP on_IN the_DT status_NN of_IN compliance_NN activities_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2003_CD 105_CD 31_CD Assets_NNS pledged_VBN ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD Average_JJ wholesale_JJ price_NN class_NN action_NN litigation_NN In_IN January_NNP 2002_CD ,_, AstraZeneca_NNP was_VBD named_VBN as_IN a_DT defendant_NN along_IN with_IN 24_CD other_JJ pharmaceutical_JJ manufacturers_NNS in_IN a_DT class_NN action_NN suit_NN ,_, in_IN Massachusetts_NNP ,_, brought_VBD on_RP behalf_NN of_IN a_DT putative_JJ class_NN of_IN plaintiffs_NNS alleged_VBN to_TO have_VB overpaid_VBN for_IN prescription_NN drugs_NNS as_IN a_DT result_NN of_IN inflated_JJ wholesale_JJ list_NN prices_NNS ._.
The_DT suit_NN seeks_VBZ to_TO recover_VB unspecified_JJ damages_NNS ._.
AstraZeneca_NNP has_VBZ also_RB been_VBN named_VBN as_IN a_DT co-defendant_NN with_IN various_JJ other_JJ pharmaceutical_JJ manufacturers_NNS in_IN similar_JJ suits_NNS filed_VBN in_IN seven_CD other_JJ states_NNS ._.
Most_JJS of_IN these_DT suits_NNS have_VBP been_VBN consolidated_VBN with_IN the_DT Massachusetts_NNP action_NN for_IN pre-trial_JJ purposes_NNS pursuant_JJ to_TO federal_JJ multi-district_JJ litigation_NN procedures_NNS ._.
AstraZeneca_NNP believes_VBZ that_IN it_PRP has_VBZ meritorious_JJ defences_NNS to_TO all_DT of_IN these_DT claims_NNS ._.
Notice_NNP of_IN state_NN Attorneys_NNS General_NNP investigations_NNS into_IN Medicaid_NNP price_NN reporting_NN In_IN December_NNP 2003_CD ,_, AstraZeneca_NNP received_VBD notices_NNS from_IN multiple_JJ US_NNP state_NN Attorney_NNP General_NNP Offices_NNS requiring_VBG the_DT Company_NN to_TO retain_VB records_NNS relating_VBG to_TO Medicaid_NNP average_JJ manufacturer_NN price_NN and_CC best_JJS price_NN calculations_NNS ._.
Similar_JJ notices_NNS have_VBP been_VBN received_VBN by_IN other_JJ manufacturer_NN codefendants_NNS in_IN the_DT average_JJ wholesale_JJ price_NN class_NN action_NN litigation_NN referred_VBD to_TO above_IN ._.
These_DT notices_NNS appear_VBP to_TO have_VB been_VBN intended_VBN to_TO address_VB proposed_VBN regulations_NNS 42_CD CFR_NNP Part_NNP 447.534_CD h_NN limiting_VBG a_DT manufacturers_NNS record_NN retention_NN obligations_NNS for_IN government_NN price_NN reporting_VBG data_NNS to_TO a_DT three_CD year_NN period_NN ._.
The_DT notices_NNS from_IN the_DT Attorneys_NNP General_NNP indicate_VBP that_IN the_DT states_NNS are_VBP investigating_VBG the_DT accuracy_NN of_IN AstraZenecas_NNP average_JJ manufacturer_NN price_NN and_CC best_JJS price_NN disclosures_NNS and_CC request_NN that_IN the_DT Company_NN retains_VBZ relevant_JJ records_NNS beyond_IN the_DT three_CD year_NN limit_NN of_IN the_DT proposed_VBN regulations_NNS ._.
US_NNP Federal_NNP Trade_NNP Commission_NNP Nexium_NNP investigation_NN As_IN previously_RB disclosed_VBN by_IN the_DT Company_NN ,_, in_IN January_NNP 2003_CD AstraZeneca_NNP received_VBD a_DT Civil_JJ Investigative_NNP Demand_NN from_IN the_DT US_NNP Federal_NNP Trade_NNP Commission_NNP FTC_NNP for_IN certain_JJ information_NN concerning_VBG AstraZenecas_NNP advertising_NN and_CC marketing_NN of_IN Nexium_NNP ._.
In_IN July_NNP 2003_CD ,_, the_DT FTC_NNP closed_VBD its_PRP$ investigation_NN without_IN action_NN ._.
Retail_JJ pharmacies_NNS drug_NN purchasers_NNS actions_NNS Since_IN October_NNP 1993_CD ,_, several_JJ thousand_CD retail_JJ pharmacies_NNS and_CC certain_JJ retail_JJ drug_NN purchasers_NNS have_VBP commenced_VBN purported_JJ class_NN actions_NNS and_CC individual_JJ actions_NNS in_IN various_JJ federal_JJ and_CC state_NN courts_NNS throughout_IN the_DT US_NNP alleging_VBG that_IN ,_, with_IN respect_NN to_TO brand_NN name_NN prescription_NN drugs_NNS ,_, manufacturers_NNS and_CC wholesalers_NNS engaged_VBN in_IN discriminatory_JJ pricing_NN practices_NNS ,_, discriminatory_JJ discounting_NN and_CC rebate_NN practices_NNS ,_, and_CC or_CC conspired_VBN with_IN one_CD another_DT to_TO fix_VB prices_NNS and_CC artificially_RB maintain_VBP high_JJ prices_NNS to_TO the_DT plaintiffs_NNS in_IN restraint_NN of_IN trade_NN and_CC commerce_NN ._.
More_JJR than_IN 20_CD brand_NN name_NN prescription_NN drug_NN manufacturers_NNS and_CC eight_CD wholesalers_NNS have_VBP been_VBN named_VBN defendants_NNS in_IN some_DT or_CC all_DT of_IN these_DT suits_NNS ._.
In_IN January_NNP 2003_CD ,_, an_DT Alabama_NNP state_NN court_NN granted_VBD AstraZenecas_NNP motion_NN to_TO dismiss_VB the_DT consumer_NN action_NN pending_VBG in_IN Alabama_NNP ._.
The_DT plaintiffs_NNS time_NN to_TO appeal_VB that_DT order_NN of_IN dismissal_NN has_VBZ expired_VBN ._.
AstraZeneca_NNP has_VBZ settled_VBN or_CC been_VBN dismissed_VBN from_IN all_DT of_IN the_DT cases_NNS except_IN for_IN a_DT retail_JJ case_NN pending_VBG in_IN the_DT Northern_NNP District_NNP of_IN Illinois_NNP ._.
AstraZeneca_NNP has_VBZ consistently_RB denied_VBN liability_NN and_CC continues_VBZ to_TO believe_VB it_PRP has_VBZ meritorious_JJ defencesto_NN the_DT remaining_VBG claims_NNS ._.
Additional_JJ government_NN investigations_NNS into_IN drug_NN marketing_NN practices_NNS As_IN is_VBZ true_JJ for_IN most_JJS ,_, if_IN not_RB all_DT ,_, major_JJ prescription_NN pharmaceutical_JJ companies_NNS operating_VBG in_IN the_DT US_NNP ,_, AstraZeneca_NNP is_VBZ currently_RB involved_VBN in_IN multiple_JJ additional_JJ US_NNP federal_JJ and_CC state_NN criminal_JJ and_CC civil_JJ investigations_NNS into_IN drug_NN marketing_NN and_CC pricing_NN practices_NNS ._.
AstraZeneca_NNP has_VBZ received_VBN subpoenas_NNS from_IN the_DT US_NNP Attorneys_NNP Office_NNP in_IN Boston_NNP requesting_VBG production_NN of_IN documents_NNS relating_VBG to_TO the_DT sale_NN and_CC promotion_NN of_IN Prilosec_NNP to_TO the_DT New_NNP England_NNP Medical_NNP Center_NNP in_IN Boston_NNP ._.
A_DT separate_JJ subpoena_NN from_IN the_DT same_JJ office_NN requests_NNS documents_NNS relating_VBG to_TO the_DT sale_NN and_CC marketing_NN of_IN products_NNS to_TO an_DT individual_JJ physician_NN in_IN Worcester_NNP ,_, Massachusetts_NNP and_CC certain_JJ physicians_NNS and_CC entities_NNS affiliated_VBN with_IN that_DT physician_NN ._.
AstraZeneca_NNP has_VBZ also_RB received_VBN a_DT subpoena_NN from_IN the_DT Massachusetts_NNP Attorney_NNP Generals_NNP Office_NNP seeking_VBG documents_NNS relating_VBG to_TO the_DT sale_NN and_CC promotion_NN of_IN five_CD products_NNS Prilosec_NNP ,_, Seroquel_NNP ,_, Rhinocort_NNP Aqua_NNP ,_, Toprol-XL_NNP and_CC Zestril_NNP within_IN Massachusetts_NNP ._.
AstraZeneca_NNP has_VBZ received_VBN an_DT investigative_JJ demand_NN from_IN the_DT Missouri_NNP Attorney_NNP Generals_NNP Office_NNP seeking_VBG documents_NNS and_CC information_NN relating_VBG to_TO agreements_NNS with_IN drug_NN retailers_NNS doing_VBG business_NN within_IN Missouri_NNP ._.
AstraZeneca_NNP is_VBZ co-operating_VBG with_IN these_DT investigations_NNS ._.
It_PRP is_VBZ not_RB possible_JJ to_TO predict_VB the_DT outcome_NN of_IN any_DT of_IN these_DT investigations_NNS ,_, which_WDT could_MD include_VB the_DT payment_NN of_IN damages_NNS and_CC the_DT imposition_NN of_IN fines_NNS ,_, penalties_NNS and_CC administrative_JJ remedies_NNS ._.
General_NNP With_IN respect_NN to_TO each_DT of_IN the_DT legal_JJ proceedings_NNS described_VBN above_IN ,_, other_JJ than_IN those_DT which_WDT have_VBP been_VBN disposed_VBN of_IN ,_, we_PRP are_VBP unable_JJ to_TO make_VB estimates_NNS of_IN the_DT loss_NN or_CC range_NN of_IN losses_NNS at_IN this_DT stage_NN ._.
We_PRP also_RB do_VBP not_RB believe_VB that_IN disclosure_NN of_IN the_DT amount_NN sought_VBN by_IN plaintiffs_NNS ,_, if_IN that_DT is_VBZ known_VBN ,_, would_MD be_VB meaningful_JJ with_IN respect_NN to_TO those_DT legal_JJ proceedings_NNS ._.
This_DT is_VBZ due_JJ to_TO a_DT number_NN of_IN factors_NNS including_VBG for_IN example_NN ,_, the_DT stage_NN of_IN the_DT proceedings_NNS in_IN many_JJ cases_NNS trial_NN dates_NNS have_VBP not_RB been_VBN set_VBN and_CC overall_JJ length_NN and_CC extent_NN of_IN legal_JJ discovery_NN ,_, the_DT entitlement_NN of_IN the_DT parties_NNS to_TO an_DT action_NN to_TO appeal_VB a_DT decision_NN ,_, clarity_NN as_IN to_TO theories_NNS of_IN liability_NN ,_, damages_NNS and_CC governing_VBG law_NN ,_, uncertainties_NNS in_IN timing_NN of_IN litigation_NN ,_, and_CC the_DT possible_JJ need_NN for_IN further_JJ legal_JJ proceedings_NNS to_TO establish_VB the_DT appropriate_JJ amount_NN of_IN damages_NNS ,_, if_IN any_DT ._.
However_RB ,_, although_IN there_EX can_MD be_VB no_DT assurance_NN regarding_VBG the_DT outcome_NN of_IN any_DT of_IN the_DT legal_JJ proceedings_NNS or_CC investigations_NNS referred_VBD to_TO in_IN this_DT Note_NN 31_CD to_TO the_DT Financial_NNP Statements_NNP ,_, we_PRP do_VBP not_RB expect_VB them_PRP to_TO have_VB a_DT materially_RB adverse_JJ effect_NN on_IN our_PRP$ financial_JJ position_NN or_CC profitability_NN ._.
